205) fever) is a pulmonary and systemic fungal disease with increasing incidence and expa |
206) s the epidemiologic heterogeneity of this disease with the clinical survey, and disc |
207) greatest relative impact on risk of early disease, with a monotonic decrease over ti |
208) has declared the outbreak of coronavirus disease (COVID-19) a worldwide pandemic. |
209) Considering the current coronavirus disease (COVID-19) pandemic, telerehabilit |
210) their territories, during the coronavirus disease (COVID-19) pandemic. |
211) s and makes it easier for the coronavirus disease (COVID-19) to invade the lung tiss |
212) The coronavirus disease-19 (COVID-19) pandemic has forced |
213) Coronavirus disease-2019 (COVID-19) had an unprecedent |
214) classify germline BCL11B-dependent atopic disease as a novel primary atopic disorder |
215) dministered to adult patients with celiac disease as an adjunct therapeutic to enhan |
216) All 13 studies included enteric disease as an outcome and 11 studies evalu |
217) sions, the WHO recommends classifying the disease as dengue with or without warning |
218) aturally occurring infectious respiratory disease, as reported in the literature. |
219) to understanding the genetic basis of the disease, as well as detecting at-risk indi |
220) ain etiological agent of aspergillosis, a disease characterized by a noninvasive pro |
221) lized gastric amyloidosis (LGA) is a rare disease characterized by abnormal extracel |
222) SLE is a clinically heterogeneous disease characterized by an unpredictable |
223) rtension (PAH) is a rare and chronic lung disease characterized by progressive occlu |
224) phic Lateral Sclerosis is a neuromuscular disease characterized by the progressive d |
225) hypertension (PAH) is a devastating lung disease characterized by the progressive o |
226) e, a quality deemed essential for chronic disease management and health promotion. |
227) cognized as an essential end point in the disease management of chronic conditions s |
228) nt-facing apps supporting promote chronic disease management. |
229) ing, informed patient, collaboration, and disease management. |
230) ss the quality of mobile apps for chronic disease management. |
231) at can aid in tumor monitoring throughout disease management. |
232) ls paralleled several indices of COVID-19 disease severity (e.g., kidney dysfunction |
233) ailable noninvasive markers for assessing disease severity and mortality risk in pul |
234) standing of host determinants that impact disease severity and offer potential thera |
235) ffer from high-intensity inflammation and disease severity than the female populatio |
236) itis severity, we asked if Ket/Xyl affect disease severity. |
237) contracting COVID-19, taking into account disease severity. |
|